期刊
PLOS COMPUTATIONAL BIOLOGY
卷 16, 期 8, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pcbi.1008107
关键词
-
资金
- US National Institutes of Health (NIH) [R01AI106398-01]
- Bill and Melinda Gates Foundation [OPP1031105]
- Grand Challenges in Global [Health-11]
- Bill and Melinda Gates Foundation [OPP1031105] Funding Source: Bill and Melinda Gates Foundation
Standard treatment for active tuberculosis (TB) requires drug treatment with at least four drugs over six months. Shorter-duration therapy would mean less need for strict adherence, and reduced risk of bacterial resistance. A system pharmacology model of TB infection, and drug therapy was developed and used to simulate the outcome of different drug therapy scenarios. The model incorporated human immune response, granuloma lesions, multi-drug antimicrobial chemotherapy, and bacterial resistance. A dynamic population pharmacokinetic/pharmacodynamic (PK/PD) simulation model including rifampin, isoniazid, pyrazinamide, and ethambutol was developed and parameters aligned with previous experimental data. Population therapy outcomes for simulations were found to be generally consistent with summary results from previous clinical trials, for a range of drug dose and duration scenarios. An online tool developed from this model is released as open source software. The TB simulation tool could support analysis of new therapy options, novel drug types, and combinations, incorporating factors such as patient adherence behavior. Author summary A comprehensivein-silicomodel of pulmonary tuberculosis successfully predicted previous clinical trials and could simulate future therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据